3 Hospital Network Operator, Respiratory Medicines Leader and Infusion and Catheter Devices Maker Stocks With a Strong Future Roadmap: Fortis Healthcare, Cipla and Poly Medicure

Hospital, respiratory pharma and device stocks let investors follow companies that serve a growing part of the Indian economy. Fortis Healthcare, Cipla and Poly Medicure cover a multi-specialty hospital network, a respiratory and anti-infective leader and a single-use medical devices maker.

This list covers three hospital, respiratory pharma and device stocks with complete current figures: Fortis Healthcare, Cipla and Poly Medicure. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital, Respiratory Pharma and Device Stocks?

Hospital, respiratory pharma and device stocks are listed healthcare companies that run hospitals, sell medicines and export medical devices. Their earnings depend on patient volumes, prescriptions, device orders and pricing.

Hospital, Respiratory Pharma and Device Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing hospital, respiratory pharma and device stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Hospital, Respiratory Pharma and Device Stocks Have a Strong Roadmap in India?

Hospital, respiratory pharma and device stocks have a strong roadmap in India because rising insurance cover, wider healthcare access and global demand for devices keep lifting the revenue base.

• Hospital beds. New capacity adds patient volumes.
• Respiratory care. Chronic therapy brands retain loyal patients.
• Device exports. Single-use devices find buyers in many countries.

Why Fortis Healthcare Features Among These Hospital, Respiratory Pharma and Device Stocks

Among the hospital, respiratory pharma and device stocks on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.

In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%.

Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.

Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Why Cipla Features Among These Hospital, Respiratory Pharma and Device Stocks

Among the private hospital operator shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.

The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.

Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore.

Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What to watch: Follow new product launches in the United States and the growth of key domestic brands.

Why Poly Medicure Features Among These Hospital, Respiratory Pharma and Device Stocks

Among the three companies on this list, Poly Medicure makes single-use medical devices such as infusion sets, syringes, catheters, blood management products and dialysis consumables, and it exports to many countries.

Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%.

In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6.

Roadmap: The company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.

What to watch: Track export growth, new product approvals and plant capacity use.

Fortis Healthcare vs Cipla vs Poly Medicure on Key Financials

The table below sets the three hospital, respiratory pharma and device stocks side by side on revenue, profit and margin, using reported figures.

Cipla posts the highest return on equity in this group at 11.3%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Poly Medicure shows the fastest revenue growth with a 20.0% compound annual rate. A useful habit with hospital, respiratory pharma and device stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Hospital, Respiratory Pharma and Device Stocks

Every theme carries risks that deserve a check before any decision. For these hospital, respiratory pharma and device stocks, the main points are: Long-term private hospital operator shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Capacity timing. New beds take time to mature.
• Regulatory checks. Approvals and inspections can affect timelines.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital, respiratory pharma and device stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital, Respiratory Pharma and Device Stocks

Hospital, respiratory pharma and device stocks reward investors who follow demand trends, order books and margins together. Fortis Healthcare, Cipla and Poly Medicure each have a clear plan to grow. Based on the 26 October 2026 close, Fortis Healthcare trades at Rs 734.7, Cipla at Rs 1,355 and Poly Medicure at Rs 1,443.5.

Download the Univest iOS App or Univest Android App to track hospital, respiratory pharma and device stocks, set price alerts and get research-backed stock ideas.

What are hospital, respiratory pharma and device stocks?

Ans. Hospital, respiratory pharma and device stocks are listed healthcare companies that run hospitals, sell medicines and export medical devices. Their earnings depend on patient volumes, prescriptions, device orders and pricing. This list looks at three of them, Fortis Healthcare, Cipla and Poly Medicure, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which hospital, respiratory pharma and device stocks are covered in this list?

Ans. This list covers Fortis Healthcare, Cipla and Poly Medicure. Based on the 26 October 2026 close, Fortis Healthcare traded at Rs 734.7, Cipla at Rs 1,355 and Poly Medicure at Rs 1,443.5. Their return on equity ranges from 10.4% to 11.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 20.0%.

Why do hospital, respiratory pharma and device stocks have a strong future roadmap in India?

Ans. Hospital, respiratory pharma and device stocks have a strong roadmap in India because rising insurance cover, wider healthcare access and global demand for devices keep lifting the revenue base. The main drivers are as follows. Hospital beds. New capacity adds patient volumes. Respiratory care. Chronic therapy brands retain loyal patients. Device exports. Single-use devices find buyers in many countries. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Fortis Healthcare performed financially?

Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

How has Cipla performed financially?

Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

How has Poly Medicure performed financially?

Ans. Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6. Looking ahead, the company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.

What risks should investors check before buying hospital, respiratory pharma and device stocks?

Ans. Investors should check a few risks before buying hospital, respiratory pharma and device stocks. Capacity timing. New beds take time to mature. Regulatory checks. Approvals and inspections can affect timelines. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital, respiratory pharma and device stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.